EMA Panel Rejects Abaloparatide for Osteoporosis – Medscape

EMA Panel Rejects Abaloparatide for OsteoporosisMedscapeRadius has just reported more data from this trial, at the recent ENDO 2018 meeting. In follow-up of ACTIVExtend, sequential treatment with abaloparatide followed by alendronate led to greater increases in bone mineral density (BMD) in women with …

Source:: Osteoporosis Feed

      

Last modified: March 23, 2018